Credit score: Unsplash/CC0 Public Area
A examine performed utilizing digital well being report knowledge from a collective of U.S. well being care techniques discovered that the majority adults with obese or weight problems discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) remedy inside one yr. Discontinuation charges had been considerably greater and reinitiation charges had been considerably decrease for sufferers with out kind 2 diabetes.
GLP-1 RAs are used for weight administration and glycemic management, with proof suggesting that continued use is critical for sustained advantages. Considerations associated to value, tolerability, and entry could also be contributing to excessive discontinuation charges. Earlier research have reported broadly various discontinuation charges, however knowledge on reinitiation patterns stay restricted.
Within the examine, “Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity,” printed in JAMA Community Open, researchers investigated the charges at which individuals stopped utilizing the favored weight reduction medicine.
A retrospective cohort evaluation included 125,474 adults with obese or weight problems who initiated remedy with liraglutide, semaglutide, or tirzepatide between January 1, 2018, and December 31, 2023. Eligible sufferers had a physique mass index of 27 or greater, a weight measurement inside 60 days earlier than initiation, and common well being care interactions within the earlier yr.
Discontinuation was outlined as 60 days with none GLP-1 RA available. Reinitiation was outlined as the primary fill of any GLP-1 RA after discontinuation. Sufferers had been adopted for as much as two years for discontinuation and two further years for reinitiation. Time-to-event outcomes had been assessed utilizing Kaplan-Meier fashions and Cox proportional hazards regression.
Proportions Discontinuing and Reinitiating Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Inside 2 Years. Credit score: JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2024.57349
Inside one yr, 46.5% of sufferers with kind 2 diabetes and 64.8% with out kind 2 diabetes discontinued GLP-1 RA remedy. Inside two years, discontinuation charges elevated to 64.1% and 84.4%, respectively. Gastrointestinal antagonistic occasions had been linked to the discontinuation charges.
Amongst 41,792 sufferers who discontinued and had a weight measurement at discontinuation, 47.3% of sufferers with kind 2 diabetes and 36.3% with out kind 2 diabetes reinitiated remedy inside one yr. Weight regain was considerably related to reinitiation, with a 1% weight achieve rising the hazard by 2.3% for sufferers with kind 2 diabetes and a pair of.8% for these with out. Sufferers aged 65 years or older had been much less prone to reinitiate remedy.
GLP-1 RA discontinuation charges had been excessive, notably for sufferers with out kind 2 diabetes, who additionally had decrease reinitiation charges. Weight reduction throughout remedy was related to decrease discontinuation, whereas weight regain after discontinuation was linked to greater reinitiation.
Extra info:
Patricia J. Rodriguez et al, Discontinuation and Reinitiation of Twin-Labeled GLP-1 Receptor Agonists Amongst US Adults With Obese or Weight problems, JAMA Community Open (2025). DOI: 10.1001/jamanetworkopen.2024.57349
© 2025 Science X Community
Quotation:
Many adults cease GLP-1 remedy inside a yr with low restart charges, evaluation finds (2025, February 19)
retrieved 19 February 2025
from https://medicalxpress.com/information/2025-02-adults-glp-therapy-year-restart.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
